FDA looking into death of 14-year-old trial participant
Updated: Tuesday, March 5 2013, 08:15 AM EST
(NEWSCHANNEL 3) - Federal health regulators say they've stopped Amgen's studies of its thyroid drug Sensipar, after the death of a 14-year-old patient in a company trial.
The FDA says that it's gathering information about the death, but has shut down all studies of the drug in children.
Sensipar is approved for adults to treat over-activitiy of the parathyroid gland.
Amgen had been studying the drug to see whether it works in children.
Related Stories
- Midland weighs repairs to flood-damaged city parks
- Stink bug threatens Mich. fruit, vegetable crops
- Work done at ex-brownfield site on Detroit River
- Sheriff: SW Michigan man drove farm tractor drunk
- Grand Rapids club closes stairwell where 3 died
- Remains of Native Americans are buried in Michigan
- 3 in Mich. win $250,000 in Mega Millions lottery
- Honda to give Detroit orchestra $150K for youth
- Rockford field for children with disabilities.
- Michigan lawmaker backs anti-cyber-bullying bill










Social